Golden State Wealth Management LLC Acquires 98 Shares of CME Group Inc. (NASDAQ:CME)

Golden State Wealth Management LLC boosted its holdings in CME Group Inc. (NASDAQ:CME) by 612.5% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 114 shares of the financial services provider’s stock after buying an additional 98 shares during the period. Golden State Wealth Management LLC’s holdings in CME Group were worth $30,000 as of its most recent SEC filing.

Other institutional investors also recently added to or reduced their stakes in the company. New Age Alpha Advisors LLC grew its holdings in shares of CME Group by 50.0% during the 4th quarter. New Age Alpha Advisors LLC now owns 129 shares of the financial services provider’s stock worth $30,000 after purchasing an additional 43 shares in the last quarter. Alpine Bank Wealth Management acquired a new stake in shares of CME Group during the 1st quarter worth approximately $32,000. Knuff & Co LLC acquired a new stake in shares of CME Group during the 4th quarter worth approximately $33,000. Banque Transatlantique SA acquired a new stake in shares of CME Group during the 4th quarter worth approximately $35,000. Finally, United Community Bank acquired a new stake in shares of CME Group during the 4th quarter worth approximately $37,000. 87.75% of the stock is owned by institutional investors.

CME Group Trading Down 0.4%

Shares of CME opened at $274.83 on Monday. The stock has a fifty day moving average price of $276.40 and a two-hundred day moving average price of $258.18. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.02 and a current ratio of 1.02. CME Group Inc. has a 52-week low of $193.17 and a 52-week high of $290.79. The company has a market cap of $99.04 billion, a price-to-earnings ratio of 27.65, a PEG ratio of 3.75 and a beta of 0.44.

CME Group (NASDAQ:CME) last released its earnings results on Wednesday, April 23rd. The financial services provider reported $2.80 earnings per share for the quarter, topping analysts’ consensus estimates of $2.61 by $0.19. The company had revenue of $1.64 billion during the quarter, compared to the consensus estimate of $1.56 billion. CME Group had a return on equity of 14.03% and a net margin of 57.71%. The firm’s quarterly revenue was up 10.4% on a year-over-year basis. During the same quarter in the previous year, the company posted $2.50 earnings per share. Analysts predict that CME Group Inc. will post 10.49 EPS for the current fiscal year.

CME Group Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Wednesday, June 25th. Stockholders of record on Monday, June 9th were given a dividend of $1.25 per share. The ex-dividend date was Monday, June 9th. This represents a $5.00 dividend on an annualized basis and a dividend yield of 1.82%. CME Group’s payout ratio is currently 50.30%.

Insider Activity at CME Group

In other news, Director William R. Shepard bought 256 shares of the company’s stock in a transaction dated Wednesday, June 25th. The stock was bought at an average price of $270.53 per share, for a total transaction of $69,255.68. Following the completion of the transaction, the director directly owned 258,196 shares in the company, valued at $69,849,763.88. The trade was a 0.10% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Charles P. Carey sold 500 shares of the business’s stock in a transaction on Tuesday, June 10th. The stock was sold at an average price of $265.35, for a total value of $132,675.00. Following the sale, the director owned 4,900 shares of the company’s stock, valued at approximately $1,300,215. The trade was a 9.26% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 13,400 shares of company stock valued at $3,680,610 over the last quarter. 0.30% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several research firms recently commented on CME. Morgan Stanley raised their target price on CME Group from $301.00 to $304.00 and gave the stock an “overweight” rating in a research report on Thursday, April 24th. Raymond James Financial upgraded CME Group from a “market perform” rating to an “outperform” rating and set a $287.00 target price for the company in a research report on Monday, March 10th. Oppenheimer raised their target price on CME Group from $282.00 to $300.00 and gave the stock an “outperform” rating in a research report on Wednesday, June 4th. Wall Street Zen upgraded CME Group from a “sell” rating to a “hold” rating in a research report on Saturday. Finally, JPMorgan Chase & Co. cut their target price on CME Group from $223.00 to $211.00 and set an “underweight” rating for the company in a research report on Thursday, April 24th. Three equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $259.87.

CME Group Profile

CME Group Inc, together with its subsidiaries, operates contract markets for the trading of futures and options on futures contracts worldwide. It offers futures and options products based on interest rates, equity indexes, foreign exchange, agricultural commodities, energy, and metals, as well as fixed income and foreign currency trading services.